Subscribe
1 August 2024NewsAmericasMuireann Bolger

Teva asks Fed Circ to reverse inhaler patents loss

Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva secures stay on Orange Book inhaler patent delisting
18 June 2024   New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
Teva secures stay on Orange Book inhaler patent delisting
18 June 2024   New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.

More on this story

Big Pharma
Teva secures stay on Orange Book inhaler patent delisting
18 June 2024   New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.

More features

Sandoz wins $137.2m payout for lost profits in generic launch
Dexcom suffers second patent revocation at hands of UPC
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
HLK adds CRISPR specialist as partner